肺炎克雷伯菌疫苗价值概况
世界卫生组织将其疫苗列为优先,孕妇接种或可降低后代侵袭性疾病风险,高危人群也为潜在目标。该疫苗价值概况由多领域专家组与世卫组织利益相关方合作、仅基于现有公开信息制定。
要点
- 肺炎克雷伯菌是归因于耐药细菌死亡的第二大病原体。
- 世界卫生组织将针对肺炎克雷伯菌的疫苗列为优先。
核心结论
- 针对肺炎克雷伯菌的疫苗被世界卫生组织列为优先,孕妇接种或可降低其年幼后代的侵袭性肺炎克雷伯菌病风险。
- 该疫苗价值概况旨在为肺炎克雷伯菌疫苗及其他预防和治疗手段的潜在公共卫生、经济和社会价值提供高层面的整体评估。
研究设计与样本
- 该疫苗价值概况由来自学术界、非营利组织、公私合作组织和多边组织的主题专家工作组制定,并与世界卫生组织的利益相关方合作。
- 该疫苗价值概况仅使用现有和公开可用的信息制定。
主要发现
- 肺炎克雷伯菌是归因于抗微生物药物耐药细菌死亡的第二大病原体。
- 社区和医院获得性感染中抗微生物药物耐药性的上升对新生儿和婴儿构成关注,因其为侵袭性细菌性疾病的高风险人群。
- 治疗多重耐药感染的新抗生素研发管线有限。
- 孕妇接种肺炎克雷伯菌疫苗或可降低其年幼后代发生侵袭性肺炎克雷伯菌病的风险。
临床怎么用
- 该疫苗价值概况考虑对孕妇接种以保护其婴儿从出生至至少三个月龄,并考虑其他高风险人群。
局限性
- 该疫苗价值概况仅使用现有和公开可用的信息制定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Klebsiella pneumoniae causes community- and healthcare-associated infections in children and adults. Globally in 2019, an estimated 1.27 million (95% Uncertainty Interval [UI]: 0.91-1.71) and 4.95 million (95% UI: 3.62-6.57) deaths were attributed to and associated with bacterial antimicrobial resistance (AMR), respectively. K. pneumoniae was the second leading pathogen in deaths attributed to AMR resistant bacteria. Furthermore, the rise of antimicrobial resistance in both community- and hospital-acquired infections is a concern for neonates and infants who are at high risk for invasive bacterial disease. There is a limited antibiotic pipeline for new antibiotics to treat multidrug resistant infections, and vaccines targeted against K. pneumoniae are considered to be of priority by the World Health Organization. Vaccination of pregnant women against K. pneumoniae could reduce the risk of invasive K.pneumoniae disease in their young offspring. In addition, vulnerable children, adolescents and adult populations at risk of K. pneumoniae disease with underlying diseases such as immunosuppression from underlying hematologic malignancy, chemotherapy, patients undergoing abdominal and/or urinary surgical procedures, or prolonged intensive care management are also potential target groups for a K. pneumoniae vaccine. A 'Vaccine Value Profile' (VVP) for K.pneumoniae, which contemplates vaccination of pregnant women to protect their babies from birth through to at least three months of age and other high-risk populations, provides a high-level, holistic assessment of the available information to inform the potential public health, economic and societal value of a pipeline of K. pneumoniae vaccines and other preventatives and therapeutics. This VVP was developed by a working group of subject matter experts from academia, non-profit organizations, public-private partnerships, and multi-lateral organizations, and in collaboration with stakeholders from the WHO. All contributors have extensive expertise on various elements of the K.pneumoniae VVP and collectively aimed to identify current research and knowledge gaps. The VVP was developed using only existing and publicly available information.
引用
- Dangor Z, Benson N, Berkley JA, et al. Vaccine value profile for Klebsiella pneumoniae. Vaccine. 2024. PMID: 38503661. doi:10.1016/j.vaccine.2024.02.072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。